Preferred Stock Channel
Quotes delayed 20 minutes


Strong Buy (4.00 out of 4)
95th percentile
(ranked higher than approx. 95% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
www.valueforum.com/7/
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Saturday, December 7, 11:05 AM

Slide #264. CTI BioPharma Corp. Preferred Stock Offering

Company: CTI BioPharma Corp. (NASDAQ:CTIC)
Date announced: 11/6/2014
Shares Offered: 35,000
Date of Pricing: 11/7/2014
Price Per Share: $1,000
Preferred Stock Offering Details: CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 35,000 shares of its Series 21 Preferred Stock, offered at a price to the public of $1,000 per share of Series 21 Preferred Stock (the "Offering"). Each share of Series 21 Preferred Stock is convertible at the option of the holder, at any time, into 500 shares of common stock at a conversion price of $2.00 per share of common stock, for a total of 17.5 million shares of common stock. The shares of Series 21 Preferred Stock will automatically convert into shares of common stock in certain circumstances. Shares of the Series 21 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events. The Series 21 Preferred Stock will have no voting rights on general corporate matters.

CTI BioPharma is a biopharmaceutical company. Co. focuses on treatments that target blood-related cancers where there is an unmet medical need and is primarily focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. Co.'s primary development candidate, pacritinib, is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. PIXUVRI is an aza-anthracenedione which has been granted conditional marketing authorization by the European Commission in the European Union, as a monotherapy for the treatment of adult patients with various relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Open the CTIC Page at Preferred Stock Channel »

Name:  CTI BioPharma Corp
Website:  www.celltherapeutics.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding CTIC:  3 (see which ones)
Total Market Value Held by ETFs:  $1,164,751
Total Market Capitalization:  $53,000,000
% of Market Cap. Held by ETFs:  2.20%
 

Open the CTIC Page at Preferred Stock Channel (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 264 of 475 | www.PreferredStockChannel.com | Copyright © 2011 - 2019, All Rights Reserved

Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.